<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Mol. Neurosci.</journal-id>
<journal-title>Frontiers in Molecular Neuroscience</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Mol. Neurosci.</abbrev-journal-title>
<issn pub-type="epub">1662-5099</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fnmol.2023.1135491</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Molecular Neuroscience</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: Molecular mechanisms in neural development, related disorders, and therapeutic treatments</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Kumar</surname> <given-names>Vijay</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1725434/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Bishayee</surname> <given-names>Kausik</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/490317/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Kim</surname> <given-names>Jaebong</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1709242/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Biochemistry, College of Medicine, Institute of Cell Differentiation and Aging, Hallym University</institution>, <addr-line>Chuncheon</addr-line>, <country>South Korea</country></aff>
<aff id="aff2"><sup>2</sup><institution>Biomedical Science Core-Facility, Soonchunhyang Institute of Medi-Bio Science, Soonchunhyang University</institution>, <addr-line>Cheonan-si</addr-line>, <country>South Korea</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited and reviewed by: Jean-Marc Taymans, Institut National de la Sant&#x000E9; et de la Recherche M&#x000E9;dicale (INSERM), France</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Jaebong Kim &#x02709; <email>jbkim&#x00040;hallym.ac.kr</email></corresp>
<fn fn-type="other" id="fn001"><p>This article was submitted to Molecular Signalling and Pathways, a section of the journal Frontiers in Molecular Neuroscience</p></fn></author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>01</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>16</volume>
<elocation-id>1135491</elocation-id>
<history>
<date date-type="received">
<day>31</day>
<month>12</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>04</day>
<month>01</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2023 Kumar, Bishayee and Kim.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Kumar, Bishayee and Kim</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<related-article id="RA1" related-article-type="commentary-article" xlink:href="https://www.frontiersin.org/research-topics/35406/molecular-mechanisms-in-neural-development-related-disorders-and-therapeutic-treatments" ext-link-type="uri">Editorial on the Research Topic <article-title>Molecular mechanisms in neural development, related disorders, and therapeutic treatments</article-title>
</related-article>
<kwd-group>
<kwd>neurological disease</kwd>
<kwd>signaling</kwd>
<kwd>genetic factors</kwd>
<kwd>diagnosis</kwd>
<kwd>therapeutic treatment</kwd>
</kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="6"/>
<page-count count="2"/>
<word-count count="1398"/>
</counts>
</article-meta>
</front>
<body>
<p>Despite the availability of treatments or modern prevention methods, neurological diseases are the leading cause of death and a considerable global concern, affecting overall human health (Chin and Vora, <xref ref-type="bibr" rid="B1">2014</xref>). Neurological research requires sustained efforts to investigate disease etiology and pathogenesis and develop diagnostic and prevention strategies. Increasing evidence suggests that neural pathogenesis is associated with compromised molecular events driving neuronal development, shaping, and functionality, which may occur at any stage of life. Neurons exhibit limited regenerative capacity, which demands a deep understanding of the molecular mechanisms underlying the pathogenic causes, including genetic factors, flawed molecules, signaling pathways, and loss/gain-of enzyme activity. Recently, remarkable progress has been made in identifying the target molecules and their association with pathophysiological processes. This Research Topic aims to analyze the molecular events, associated biomolecules, signaling pathways, and mechanisms underlying neurological diseases and their applicability as potential therapeutic targets.</p>
<p>Among the several types of brain tumors, glioma is the most common intra-axial tumor originating from glial cells and accounts for 33 % of all the brain tumors (Hanif et al., <xref ref-type="bibr" rid="B3">2017</xref>). In addition, a high recurrence and mortality rate results in only 5.5 % of the patients surviving after diagnosis for a median 14.5 to 16.6 months. Several key signaling pathways, including Hippo/YAP, Notch, Pi3K/AKT/mTOR, TGF-&#x003B2;, and Wnt/&#x003B2;-catenin, play essential roles in normal biological processes such as proliferation, differentiation, and migration. However, an irregularity in any of these signaling pathways promotes tumorigenesis and neurological disorders (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fnmol.2022.910543">Wu et al.</ext-link>). <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fnmol.2022.910543">Wu et al.</ext-link> summarized the mechanisms associated with glioma pathogenesis and alterations in signals involved in glioma progression and malignancy. Based on existing evidence, they explored the possibility of targeting key molecules or pathways, such as Notch, Yap1, and miRNA, which may help develop treatment and diagnosis strategies (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fnmol.2022.910543">Wu et al.</ext-link>).</p>
<p>WNT signaling plays an essential role in neuronal development and functionality. However, impaired Wnt signaling is involved in tumorigenesis (particularly gliomagenesis). Similarly, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fnmol.2022.1017568">Alkailani et al.</ext-link> reviewed research evidence representing the active involvement of WNT signaling in brain tumorigenesis. This study primarily focused on the mechanism of WNT signaling contributing to glioblastoma (GMB) progression. For example, Wnt degradation/dysregulation in GMB progression and activation of Wnt signaling by oncogenes, such as WNTless (WLS/Gpr177), have been reported in WNT ligand secretion (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fnmol.2022.1017568">Alkailani et al.</ext-link>).</p>
<p>Autophagy is an essential cellular process implicated in various pathophysiological conditions, including cancer and neurodegenerative disorders. It is characterized by the sequestration of cellular cargo (autophagosome), which fuses with lysosomes to degrade harmful molecules (Meng et al., <xref ref-type="bibr" rid="B5">2019</xref>). Due to enlarged dendritic and axonal cytoplasm, autophagic vacuoles (AV) travel considerable distances to fuse with lysosomes. Thus, the hindering of organelle transport in neurons causes the accumulation of AV and other waste over time, which promotes neurodegenerative diseases such as Alzheimer&#x00027;s disease (Lee et al., <xref ref-type="bibr" rid="B4">2011</xref>). WD-repeat protein interacting with phosphoinositides (WIPI) binds to phosphoinositides and recruits autophagy proteins, thus playing an important role in autophagy. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fnmol.2022.1011918">Almannai et al.</ext-link> has summarized the biological functions of WIPI proteins (WIPI1, WIPI2, WIPI3, and WIPI4) in human diseases. Neural tube defects in a patient cohort study and convergent extension defects in WIPI1 knockdown/overexpression zebrafish indicate the crucial role of WIPI1 in neural tube formation. However, based on transcriptomic data, high WIPI1 signaling contributes to right ventricular failure (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fnmol.2022.1011918">Almannai et al.</ext-link>). Phosphorylated WIPI2 is involved in autophagosome biogenesis. In aged mice, phosphorylation misregulation triggers autophagic structure accumulation and a decline in the neuronal autophagy process. In addition, defective <italic>WIPI2</italic> induces several abnormalities such as intellectual disability, reduced brain volume, microcephaly, seizures, skeletal-related abnormalities, and dysmorphic features. WIPI3 is involved in the pathogenesis of El-Hattab-Alkuraya syndrome, with profound global developmental delay, microcephaly, early onset refractory seizures, and progressive spastic quadriplegia (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fnmol.2022.1011918">Almannai et al.</ext-link>). Furthermore, WIPI4 is associated with the pathogenesis of Beta-propeller protein-associated neurodegeneration. Therefore, the normal expression of WIPI proteins is necessary for the impaired expression of normal cellular states driving pathophysiological conditions (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fnmol.2022.1011918">Almannai et al.</ext-link>).</p>
<p>Spinocerebellar Ataxia (SCA) is an inherited neurodegenerative disorder affecting the brain cerebellum (sometimes the spinal cord) and regulates physical coordination and movement. Approximately 40 SCA types been genetically identified; among these, SCA3, accounting for approximately 35 % of the SCAs, is the most preventable form (Seidel et al., <xref ref-type="bibr" rid="B6">2012</xref>; Diallo et al., <xref ref-type="bibr" rid="B2">2021</xref>). <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fnmol.2022.919199">Li et al.</ext-link> The c.1130 C&#x0003E;T (p.T377M) mutation in the <italic>KCND3</italic> gene (encoding potassium voltage-gated channel subfamily D member 3 (Kv4. 3) protein), which induces protein misfolding and aggregation, and further endoplasmic reticulum stress collectively leads to neuronal apoptosis in SCA19/22.</p>
<sec id="s1">
<title>Closing remarks</title>
<p>Although there is increased interest in neurodegenerative diseases recently, its molecular mechanisms and pathogenic causes are still unclear. Understanding molecular factors and signaling pathways can aid in developing accurate prognosis, diagnosis, and therapeutic interventions, which are essential for treating neurodegenerative diseases.</p>
</sec>
<sec sec-type="author-contributions" id="s2">
<title>Author contributions</title>
<p>VK wrote the original draft. KB helped with revising of the manuscript. JK supervised the study. All authors have read and approved the published version of the manuscript.</p>
</sec>
</body>
<back>
<sec sec-type="funding-information" id="s3">
<title>Funding</title>
<p>This work was supported by the Basic Science Research Program of the National Research Foundation of Korea (NRF), funded by the Ministry of Education, Science, and Technology of Korea (2016R1D1A1B02008770, 2018M3C7A1056285, 2021R1A4A1027355, and 2021M3H9A1097557).</p>
</sec>
<ack><p>We thank all contributors and reviewers who participated in this research.</p>
</ack>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s4">
<title>Publisher&#x00027;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chin</surname> <given-names>J. H.</given-names></name> <name><surname>Vora</surname> <given-names>N.</given-names></name></person-group> (<year>2014</year>). <article-title>The global burden of neurologic diseases</article-title>. <source>Neurology.</source> <volume>83</volume>, <fpage>349</fpage>&#x02013;<lpage>351</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000000610</pub-id><pub-id pub-id-type="pmid">25049303</pub-id></citation></ref>
<ref id="B2">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diallo</surname> <given-names>A.</given-names></name> <name><surname>Jacobi</surname> <given-names>H.</given-names></name> <name><surname>Tezenas du Montcel</surname> <given-names>S.</given-names></name> <name><surname>Klockgether</surname> <given-names>T.</given-names></name></person-group> (<year>2021</year>). <article-title>Natural history of most common spinocerebellar ataxia: a systematic review and meta-analysis</article-title>. <source>J. Neurol</source>. <volume>268</volume>, <fpage>2749</fpage>&#x02013;<lpage>2756</lpage>. <pub-id pub-id-type="doi">10.1007/s00415-020-09815-2</pub-id><pub-id pub-id-type="pmid">32266540</pub-id></citation></ref>
<ref id="B3">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanif</surname> <given-names>F.</given-names></name> <name><surname>Muzaffar</surname> <given-names>K.</given-names></name> <name><surname>Perveen</surname> <given-names>K.</given-names></name> <name><surname>Malhi</surname> <given-names>S. M.</given-names></name> <name><surname>Simjee Sh</surname> <given-names>U.</given-names></name></person-group> (<year>2017</year>). <article-title>Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment</article-title>. <source>Asian Pac. J. Cancer Prev</source>. <volume>18</volume>, <fpage>3</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.22034/APJCP.2017.18.1.3</pub-id><pub-id pub-id-type="pmid">28239999</pub-id></citation></ref>
<ref id="B4">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>S.</given-names></name> <name><surname>Sato</surname> <given-names>Y.</given-names></name> <name><surname>Nixon</surname> <given-names>R. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer&#x00027;s-like axonal dystrophy</article-title>. <source>J. Neurosci</source>. <volume>31</volume>, <fpage>7817</fpage>&#x02013;<lpage>7830</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.6412-10.2011</pub-id><pub-id pub-id-type="pmid">21613495</pub-id></citation></ref>
<ref id="B5">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname> <given-names>T.</given-names></name> <name><surname>Lin</surname> <given-names>S.</given-names></name> <name><surname>Zhuang</surname> <given-names>H.</given-names></name> <name><surname>Huang</surname> <given-names>H.</given-names></name> <name><surname>He</surname> <given-names>Z.</given-names></name> <name><surname>Hu</surname> <given-names>Y.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Recent progress in the role of autophagy in neurological diseases</article-title>. <source>Cell Stress.</source> <volume>3</volume>, <fpage>141</fpage>&#x02013;<lpage>161</lpage>. <pub-id pub-id-type="doi">10.15698/cst2019.05.186</pub-id><pub-id pub-id-type="pmid">31225510</pub-id></citation></ref>
<ref id="B6">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seidel</surname> <given-names>K.</given-names></name> <name><surname>Siswanto</surname> <given-names>S.</given-names></name> <name><surname>Brunt</surname> <given-names>E. R.</given-names></name> <name><surname>den Dunnen</surname> <given-names>W.</given-names></name> <name><surname>Korf</surname> <given-names>H. W.</given-names></name> <name><surname>R&#x000FC;b</surname> <given-names>U.</given-names></name></person-group> (<year>2012</year>). <article-title>Brain pathology of spinocerebellar ataxias</article-title>. <source>Acta Neuropathol</source>. <volume>124</volume>, <fpage>1</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-012-1000-x</pub-id><pub-id pub-id-type="pmid">22684686</pub-id></citation></ref>
</ref-list> 
</back>
</article>